What if the curve just stays flat? How much should a Covid-19 drug cost? And what’s it like on the ground in the epicenter of the novel coronavirus?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, STAT’s Sharon Begley joins us to explain what the novel coronavirus may have in store for the U.S. this summer and beyond with a look at some grim statistical models. Then, we examine Gilead Sciences, whose upcoming decision on a price for the Covid-19 drug remdesivir underlines a controversial history of marketing expensive medicines. Finally, we talk to Ethan Weiss, a Bay Area cardiologist who flew to New York City to treat patients at the outbreak’s epicenter.
For more on what we cover, here’s the latest on pandemic modeling; here’s a deep dive on Gilead; and here’s the rest of STAT’s coronavirus coverage.
We’ll be back next Thursday evening — and every Thursday evening — so be sure to sign up on Apple Podcasts, Stitcher, Google Play, or wherever you get your podcasts.
And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].
Interested in sponsoring a future episode of “The Readout LOUD”? Email us at [email protected].